Niagen Bioscience, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 42/100
What the filing says
Niagen reported Q3 2026 net sales of $27.2M (down 20% YoY from $34.0M), with Tru Niagen contributing $23.3M. Net loss was $1.2M ($0.01 per share), though adjusted EBITDA remained positive at $0.5M. The company launched three new products: Niagen Plus At-Home Injection Kit, Niagen NanoCloud skincare (first dermatologist-tested topical), and a brand campaign with Kelly Slater. Cash grew to $69.5M with $2.6M operating cash flow in Q3; ingredient business declined due to competitive pressure, but direct e-commerce grew 13% YoY. Mass General Brigham partnership announced for large clinical trial; pharmaceutical-grade supply remains a risk.
Why this rating
Revenue decline of 20% YoY is material (~3.3% of market cap), offsetting positive cash flow and product launches. Strategic investments and cash cushion mitigate concern, but near-term headwinds in core ingredient business are real. Not transformational.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.